Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 4, 2024Blood Cancer Discovery

Abstract P38: Expanding the repertoire of physiologically relevant AML models to support new target drug discovery, compound screening, and predicting patient responses in clinical trials

View Full Paper
Ask AI
Bookmark
Share

Authors

OTOmid TavanaAstraZeneca (South Korea)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Omid Tavana (2024) studied this question.

synapsesocial.com/papers/68e75dd0b6db6435876d4cf1https://doi.org/10.1158/2643-3249.bcdsymp24-p38
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 4515: Clinically relevant AML modeling with in vitro bone marrow niche and in vivo PDX approaches.2026
  2. 2Abstract 2827: Characterization of acute myeloid leukemia PDX models with hotspot gene mutations for therapeutic evaluation2024
  3. 3Abstract 4413: Identifying genome-wide histone profiles in patient derived models of AML for predictive biomarker development2024
  4. 4A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist2025 · 1 citations
  5. 5A defined culture model for ex vivo expansion of primary AML cells preserves leukemic stem cells and clonal architecture for functional and therapeutic studies2025